Download PDF
Fortschr Neurol Psychiatr 2007; 75(5): 275-284
DOI: 10.1055/s-2006-932179
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Neuropsychiatrie des Methylphenidat bei der Aufmerksamkeits-Defizit/Hyperaktivitäts-Störung (ADHS)

Neuropsychiatric Bases of the Methylphenidate-Therapy of the Attention Deficit/Hyperactivity Disorder (ADHD)M.  Huber1, 2 , E.  Kirchler2 , H.  Niederhofer3 , L.  Gruber1
  • 1Therapie Center, Ambulanz für Kinder- und Jugendpsychiatrie, Südtiroler Kinderdorf/www.kinderdorf.it, (Ärztlicher Leiter Oberarzt Dr. Markus Huber)
  • 2Zentrum für psychische Gesundheit, Psychiatrie-Sanitätsbetrieb Bruneck/www.sb-bruneck.it, (Ärztlicher Direktor Primar Dr. Roger Pycha)
  • 3Kinder-und Jugendneuropsychiatrischer Dienst, Pädiatrie-Sanitätsbetrieb Bozen/www.sbbz.it, (Ärztlicher Direktor Prof. Dr. Klaus Pittschieler)
Further Information

Publication History

Publication Date:
17 November 2006 (online)

    Permissions and Reprints

Zusammenfassung

Hohe Prävalenz und Komorbiditätsraten mit oftmals gravierenden psychosozialen Folgen machen die Aufmerksamkeits-Defizit/Hyperaktivitätsstörung (ADHS) bei Kindern, Jugendlichen und Erwachsenen zu einer Herausforderung für Forschung und Krankenversorgung. Zahlreiche Studien sprechen für die Annahme einer dopaminergen fronto-striatalen Informationsverabeitungsstörung ADHS-Betroffener (Störung exekutiver Funktionen). Die Übersichtsarbeit stellt die neurobiochemischen Grundlagen der seit fast einem halben Jahrhundert klinisch erfolgreich angewandten Methylphenidat-Therapie bei der ADHS im Zusammenhang aktueller Forschungsergebnisse dar (MRI, f-MRI, PET, SPECT, Genmapping). Die erhöhte striatale Dopamin-Transporter-Dichte bei ADHS-Methylphenidat-Respondern wird als ein wissenschaftlich konsequentes und brauchbares Arbeitsmodell für die klinische Praxis dargestellt.

Abstract

High prevalence and high co-morbidity rates with frequently aggravating psychosocial problems make the attention-deficit/hyperactivity disorder (ADHD) of children, adolescents and adults an important target for research and healthcare. Recent findings suggest a dopaminergic fronto-striatal information processing deficit in ADHD-patients (executive functions). This review summarizes and presents, in the context of recent studies (MRI, f-MRI, PET, SPECT, Mapping Genes) the neurobiochemical bases of the methylphenidate-therapy, clinically successfully applied since almost one half century by the ADHD. The increased striatal dopamine transporter density by the ADHD-methylphenidate-responder is reported as a scientifically sound and useful clinical working model.

Schlüsselwörter

ADHS - Dopamin-Transporter - Methylphenidat

Key words

ADHD - dopamine-transporter - methylphenidate

Literatur

  • 1 Conners C K, Eisenberg L. The effects of methylphenidate on symptomatology and learning in disturbed children.  Am J Psychiat. 1963;  120 458-464
    PubMedGoogle Scholar
  • 2 Millichap J G, Fowler G W. Treatment of “minimal brain dysfunction syndromes”: Selection of drugs for children with hyperactivity and learning disabilities.  Pediatr Clin North Am. 1967;  14 (4) 767-777
    PubMedGoogle Scholar
  • 3 Barkley R A. A review of stimulant drug research with hyperactive children.  J Child Psychol Psychiatry. 1977;  18 137-165
    PubMedGoogle Scholar
  • 4 Bradley C. The behavior of children receiving benzedrine.  Am J Psychiat. 1937;  94 577-585
    PubMedGoogle Scholar
  • 5 Panizzon L. La preparazione di piridil-e piperidil-arilacetonitrili e di alcuni prodotti di trasformazione, pt.1.  Helv Chim Acta. 1944;  27 1748
    CrossrefPubMedGoogle Scholar
  • 6 AACAP . Practice Parameter for the Use of Stimulant Medication in the Treatment of Children, Adolescents and Adults.  J of the American Academy for Child and Adolescent Psychiatry. 2002;  41 Suppl.2 26-49
    PubMedGoogle Scholar
  • 7 Buitelaar J K, Montgomery S A, Zwieten-Boot B J van. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention.  Eur Neuropsychopharmacol. 2003;  13 (4) 297-304
    CrossrefPubMedGoogle Scholar
  • 8 Swanson J M, Seargent J A, Taylor E, Sonuga-Barke E J, Jensen P S, Cantwell D P. Attention-deficit disorder and hyperkinetic disorder.  Lancet. 1998;  351 (9100) 429-433
    CrossrefPubMedGoogle Scholar
  • 9 Wender P H. Attention-deficit hyperactivity disorder in adults.  Psychiatr Clin North Am. 1998;  21 (4) 761-774
    CrossrefPubMedGoogle Scholar
  • 10 Spencer T J, Biederman J, Wilens E, Faraone S V. Overview and Neurobiology of Attention-Deficit/Hyperactivity Disorder.  J Clin Psychiatry. 2002;  63 Suppl. 12 3-9
    PubMedGoogle Scholar
  • 11 Retz W, Pajonk F G, Rösler M. Eine Aufgabe für die psychiatrische Forschung und Krankenversorgung - Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Erwachsenenalter.  Psychoneuro. 2003;  29 527-531
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Steinhausen H C. Attention-deficit hyperactivity disorder in a life perspective.  Acta Psychiatr Scand. 2003;  107 (5) 321-322
    PubMedGoogle Scholar
  • 13 MTA Cooperative Group . 14-Month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder.  Arch Gen Psychiatry. 1999;  56 1073-1086
    Google Scholar
  • 14 NIH . National Institutes of Health Consensus Development Conference Statement-Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).  J Am Acad Child Adolesc Psychiatry. 2000;  39 182-193
    PubMedGoogle Scholar
  • 15 Pliszka S R, Greenhill L L, Crismon M L, Sedillo A, Carlson C, Conners C K, McCracken J T, Swanson J M, Hughes C W, Llana M E, Lopez M, Toprac M G. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I and II.  J Am Acad Child Adolesc Psychiatry. 2000;  39 (7) 908-927
    PubMedGoogle Scholar
  • 16 Vitiello B. Long-term effects of stimulant medication on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder.  J Child Adolesc Psychopharmacol. 2001;  11 (1) 25-34
    PubMedGoogle Scholar
  • 17 Döpfner M, Lehmkuhl G. Evidenzbasierte Therapie von Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS).  Prax Kinderpsychol Kinderpsychiatr. 2002;  51 (6) 419-440
    PubMedGoogle Scholar
  • 18 Leonard B E, McCartan D, White J, King D J. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects.  Hum Psychopharmacol. 2004;  19 (3) 151-180
    CrossrefPubMedGoogle Scholar
  • 19 Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.  Int J Neuropsychopharmacol. 2004;  7 (1) 77-97
    CrossrefPubMedGoogle Scholar
  • 20 Santosh P J, Taylor E. Stimulant drugs.  Eur Child Adolesc Psychiatry. 2000;  9 (1) 27-43
    CrossrefPubMedGoogle Scholar
  • 21 Spencer T J. ADHD treatment across the life cycle.  J Clin Psychiatry. 2004;  65 Suppl. 3 22-26
    PubMedGoogle Scholar
  • 22 Wilens T E, Spencer T J, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder.  J Atten Disord. 2002;  5 189-202
    PubMedGoogle Scholar
  • 23 Wilens T E. Drug therapy for adults with attention-deficit hyperactivity-disorder.  Drugs. 2003;  63 (22) 2395-2411
    CrossrefPubMedGoogle Scholar
  • 24 Fröhlich J, Lehmkuhl G. Die medikamentöse Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter.  Nervenarzt. 2004;  75 1074-1082
    CrossrefPubMedGoogle Scholar
  • 25 Pliszka S R, McCracken J T, Mass J W. Catecholamines in attention deficit hyperactivity disorder: current perspectives.  J Am Acad Child Adolesc Psychiatry. 1996;  35 (3) 264-272
    CrossrefPubMedGoogle Scholar
  • 26 Biederman J, Faraone S V. Current concepts on the neurobiology of Attention-Deficit/Hyperactivity Disorder.  J Atten Disord. 2002;  6 Suppl. 1 7-16
    PubMedGoogle Scholar
  • 27 Davids E, Zhang K, Tarazi F I, Baldessarini R J. Animals models of attention-deficit/hyperactivity disorder.  Brain Res Rev. 2003;  42 (1) 1-21
    CrossrefPubMedGoogle Scholar
  • 28 Pliszka S R. The neuropsychopharmacology of attention-deficit/hyperactivity disorder.  Biol Psychiatry. 2005;  57 (11) 1385-1390
    CrossrefPubMedGoogle Scholar
  • 29 Oades R D, Sadile A G, Sagvolden T, Viggiano D, Zuddas A, Devoto P, Aase H, Johansen E B, Ruocco L A, Russell V A. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles.  Dev Sci. 2005;  8 (2) 122-131
    Google Scholar
  • 30 Schachar R, Tannock R, Mariott M, Logan G. Deficient inhibitory control in attention deficit hyperactivity disorder.  J Abnorm Child Psychol. 1995;  23 (4) 411-437
    CrossrefPubMedGoogle Scholar
  • 31 Barkley R A. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD.  Psychol Bull. 1997;  121 (1) 65-94
    CrossrefPubMedGoogle Scholar
  • 32 Pineda D, Ardila A, Rosselli M, Cadavid C, Mancheno S, Mejia S. Executive dysfunction in children with attention deficit hyperactivity disorder.  Int J Neurosci. 1998;  96 (3 - 4) 177-196
    PubMedGoogle Scholar
  • 33 Swanson J M. Role of executive function in ADHD.  J Clin Psychiatry. 2003;  64 Suppl. 14 35-39
    PubMedGoogle Scholar
  • 34 Sonuga-Barke E J. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways.  Biol Psychiatry. 2005;  57 (11) 1231-1238
    CrossrefPubMedGoogle Scholar
  • 35 Posner M I, Dehaene S. Attentional networks.  Trends Neurosci. 1994;  17 (2) 75-79
    CrossrefPubMedGoogle Scholar
  • 36 Afifi A K. Basal ganglia: functional anatomy and physiology. Part I.  J Child Neurol. 1994;  9 (4) 249-260
    PubMedGoogle Scholar
  • 37 Masterman D L, Cummings J L. Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behaviors.  J Psychopharmacol. 1997;  11 (2) 107-114
    PubMedGoogle Scholar
  • 38 Saint-Cyr J A. Frontal-striatal circuit functions: context, sequence, and consequence.  J Int Neuropsychol Soc. 2003;  9 (1) 103-127
    CrossrefPubMedGoogle Scholar
  • 39 Kaiser S, Mundt C, Weisbrod M. Exekutive Kontrollfunktionen und Neuropsychiatrische Erkrankungen - Perspektiven für Forschung und Klinik.  Fortschr Neurol Psychiatr. 2005;  73 438-450
    PubMedGoogle Scholar
  • 40 Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.  Science. 1986;  231 (4735) 258-261
    CrossrefPubMedGoogle Scholar
  • 41 Kessler R M, Whetsell W O, Ansari M S, Votaw J R, de Paulis T, Clanton J A, Schmidt D E, Mason N S, Manning R G. Identification of extrastriatal dopamine D2-receptors in post mortem human brain with (125I) epidepride.  Brain Res. 1993;  609 (1 - 2) 237-243
    CrossrefPubMedGoogle Scholar
  • 42 Williams G V, Goldmann-Rakic P S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.  Nature. 1995;  376 (6541) 572-575
    CrossrefPubMedGoogle Scholar
  • 43 Hall H, Farde L, Halldin C, Hurd Y L, Pauli S, Sedvall G. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using (125I)epidepride.  Synapse. 1996;  23 (2) 115-123
    CrossrefPubMedGoogle Scholar
  • 44 Volkow N D, Fowler J S, Gatley S J, Logan J, Wang G J, Ding Y S, Dewey S. PET evaluation of the dopamine system of the human brain.  J Nucl Med. 1996;  37 (7) 1242-1256
    PubMedGoogle Scholar
  • 45 Gerlach M, Gsell W, Kornhuber J, Jellinger K, Krieger V, Pantucek F, Vock R, Riederer P. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.  Brain Res. 1996;  741 (1 - 2) 142-152
    CrossrefPubMedGoogle Scholar
  • 46 Mega M S, Cummings J L. Frontal-subcortical circuits and neuropsychiatric disorders.  J Neuropsychiatry Clin Neurosci. 1994;  6 (4) 358-370
    PubMedGoogle Scholar
  • 47 Arnsten A F. Catecholamine regulation of the prefrontal cortex.  J Psychopharmacol. 1997;  11 (2) 151-162
    PubMedGoogle Scholar
  • 48 Nieoullon A. Dopamine and the regulation of cognition and attention.  Prog Neurobiol. 2002;  67 (1) 53-83
    CrossrefPubMedGoogle Scholar
  • 49 Nieoullon A, Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition.  Curr Opin Neurol. 2003;  16 Suppl. 2 3-9
    PubMedGoogle Scholar
  • 50 Coull J T. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology.  Prog Neurobiol. 1998;  55 (4) 343-361
    CrossrefPubMedGoogle Scholar
  • 51 Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder.  Biol Psychiatry. 1999;  46 (9) 1234-1236
    CrossrefPubMedGoogle Scholar
  • 52 Roessner V, Banaschewski T, Uebel H, Becker A, Rothenberger A. Neuronal network models of ADHD - lateralization with respect to interhemispheric connectivity reconsidered.  Eur Child Adolesc Psychiatry. 2004;  13 Suppl. 1 171-179
    PubMedGoogle Scholar
  • 53 Faraone S V, Biederman J. Neurobiology of attention deficit hyperactivity disorder.  Biol Psychiatry. 1998;  44 (10) 951-958
    CrossrefPubMedGoogle Scholar
  • 54 Sieg K G. Neuroimaging and attention deficit disorder. In: Accardo PJ, Blondis TA, Whitman BY, Stein MA (eds). Attention deficits and hyperactivity in children and adults. New York, Basel: Marcel Dekker 2000: 73-118
    Google Scholar
  • 55 Castellanos F X, Lee P P, Sharp W, Jeffries N O, Greenstein D K, Clasen L S, Blumenthal J D, James R S, Ebens C L, Walter J M, Zijdenbos A, Evans A C, Giedd J N, Rapoport J L. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder.  JAMA. 2002;  288 (14) 1740-1748
    CrossrefPubMedGoogle Scholar
  • 56 Durston S. A review of the biological bases of ADHD: what have we learned from imaging studies?.  Ment Retard Dev Disabil Res Rev. 2003;  9 (3) 184-195
    CrossrefPubMedGoogle Scholar
  • 57 Roth R M, Saykin A J. Executive dysfunction in attention-deficit/hyperactivity disorder: cognitive and neuroimaging findings.  Psychiatr Clin North Am. 2004;  27 (1) 83-96
    CrossrefPubMedGoogle Scholar
  • 58 Bush G, Valera E M, Seidman L J. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions.  Biol Psychiatry. 2005;  57 (11) 1273-1284
    CrossrefPubMedGoogle Scholar
  • 59 Seidman L J, Valera E M, Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder.  Biol Psychiatry. 2005;  57 (11) 1263-1272
    CrossrefPubMedGoogle Scholar
  • 60 Willis W G, Weiler M D. Neural substrates of childhood attention-deficit/hyperactivity disorder: electroencephalographic and magnetic resonance imaging evidence.  Dev Neuropsychol. 2005;  27 (1) 135-182
    CrossrefPubMedGoogle Scholar
  • 61 Castellanos F X, Giedd J N, Marsh W L, Hamburger S D, Vaituzis A C, Dickstein D B, Sarfatti S E, Vauss Y C, Snell J W, Lange N, Kaysen D, Krain A L, Ritchie G F, Rajapakse J C, Rapoport J L. Quantitative brain magnetic resonance imaging in attention deficit hyperactivity disorder.  Arch Gen Psychiatry. 1996;  53 (7) 607-616
    CrossrefPubMedGoogle Scholar
  • 62 Casey B J, Castellanos F X, Giedd J N, Marsh W L, Hamburger S D, Schubert A B, Vauss Y C, Vaituzis A C, Dickstein D B, Sarfatti S E, Rapoport J L. Implication of right frontostriatal circuitry in response inhibition on attention deficit hyperactivity disorder.  J Am Acad Child Adolesc Psychiatry. 1997;  36 (3) 374-383
    PubMedGoogle Scholar
  • 63 Hynd G W, Semrud-Clikeman M, Lorys A R, Novey E S, Elipopulus D, Lyytinen H. Corpus Callosum morphology in attention deficit hyperactivity disorder: morphometric analysis of MRI.  J Learn Disabil. 1991;  24 (3) 141-146
    PubMedGoogle Scholar
  • 64 Semrud-Clikeman M, Filipek P A, Biederman J, Steingard R, Kennedy D, Renshaw P, Bekken K. Attention deficit hyperactivity disorder: Magnetic resonance imaging morphometric analysis of the corpus callosum. J.  Am Acad Child Adolesc Psychiatry. 1994;  33 (6) 875-881
    PubMedGoogle Scholar
  • 65 Giedd J N, Castellanos F X, Casey B J, Kozuch P, King A C, Hamburger S D, Rapoport J L. Quantitative morphology of the corpus callosum in attention deficit hyperactivity disorder.  Am J Psychiatry. 1994;  151 (5) 665-669
    PubMedGoogle Scholar
  • 66 Baumgardner T L, Singer H S, Denkla M B, Rubin M A, Abrams M T, Colli M J, Reiss A L. Corpus callosum morphology in children with Tourette syndrome and attention deficit hyperactivity disorder.  Neurology. 1996;  47 (2) 477-482
    PubMedGoogle Scholar
  • 67 Hynd G W, Hern C L, Novey E S, Eliopulus D, Marshall R, Gonzales J J, Voeller K K. Attention deficit hyperactivity disorder and asymmetry of the caudate nucleus.  J Child Neurol. 1993;  8 (4) 339-347
    PubMedGoogle Scholar
  • 68 Aylward E M, Reiss A H, Reader M J, Singer H S, Brown J E, Denckla M B. Basal ganglia volumes in children with attention-deficit hyperactivity disorder.  J Child Neurol. 1996;  11 (2) 112-115
    PubMedGoogle Scholar
  • 69 Overmeyer S, Bullmore E T, Suckling J, Simmons A, Williams S C, Santosh P J, Taylor E. Distributed grey and white matter deficits in hyperkinetic disorder: MRI evidence for anatomical abnormality in an attentional network.  Psychol Med. 2001;  31 (8) 1425-1435
    PubMedGoogle Scholar
  • 70 Mostofsky S H, Reiss A L, Lockhart P, Denckla M B. Evaluation of cerebellar size in attention-deficit/hyperactivity disorder.  J Child Neurol. 1998;  13 (9) 434-439
    CrossrefPubMedGoogle Scholar
  • 71 Berquin P C, Giedd J N, Jacobson L K, Hamburger S D, Krain A L, Rapoport J L, Castellanos F X. Cerebellum in attention-deficit hyperactivity disorder: a morphometric MRI study.  Neurology. 1998;  50 (4) 1087-1093
    CrossrefPubMedGoogle Scholar
  • 72 Castellanos F X, Giedd J N, Berquin P C, Walter J M, Sharp W, Tran T, Vaituzis A C, Blumenthal J D, Nelson J, Bastain T M, Zijdenbos A, Evans A C, Rapoport J L. Quantitative brain magnetic resonance imaging in girl with attention-deficit/hyperactivity disorder.  Arch Gen Psychiatry. 2001;  58 (3) 289-295
    CrossrefPubMedGoogle Scholar
  • 73 Mostofsky S H, Cooper K L, Kates W R, Denckla M B, Kaufmann W E. Smaller prefrontal and premotor volumes in boys with attention deficit/hyperactivity disorder.  Biol Psychiatry. 2002;  52 (8) 785-794
    CrossrefPubMedGoogle Scholar
  • 74 Schrimsher G W, Billingsley R L, Jackson E F, Moore B D. Caudate nucleus volume asymmetry predicts attention-deficit/hyperactivity disorder (ADHD) symptomatology in children.  J Child Neurol. 2002;  17 (12) 877-884
    PubMedGoogle Scholar
  • 75 Sowell E R, Thompson P M, Welcome S E, Henkenius A L, Toga A W, Peterson B S. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder.  The Lancet. 2003;  362 (9397) 1699-1707
    CrossrefPubMedGoogle Scholar
  • 76 Pueyo R, Maneru C, Junque C, Vendrell P, Pujol J, Mataro M, Estevez-Gonzalez A, Garcia-Sanchez C. Quantitative Signal Intensity Measures on Magnetic Resonance Imaging in Attention-Deficit Hyperactivity Disorder.  Cogn Behav Neurol. 2003;  16 (1) 75-81
    PubMedGoogle Scholar
  • 77 Bussing R, Grudnik J, Mason D, Wasiak M, Leonard C. ADHD and conduct disorder: an MRI study in a community.  World J Biol Psychiatry. 2002;  3 (4) 216-220
    PubMedGoogle Scholar
  • 78 Hill D E, Yeo R A, Campbell R A, Hart B, Vigil J, Brooks W. Magnetic resonance imaging correlates of attention-deficit/hyperactivity disorder in children.  Neuropsychology. 2003;  17 (3) 496-506
    CrossrefPubMedGoogle Scholar
  • 79 Durston S, Hulshoff Pol H E, Schnack H G, Buitelaar J K, Steenhuis M P, Minderaa R B, Kahn R S, Engeland H van. Magnetic Resonance Imaging of Boys with Attention-Deficit/Hyperactivity Disorder and Their Unaffected Siblings.  J Am Acad Child Adolesc Psychiatry. 2004;  43 (3) 332-340
    CrossrefPubMedGoogle Scholar
  • 80 Bush G, Frazier J A, Rauch S L, Seidmann L J, Whalen P J, Jenike M A, Rosen B R, Biederman J. Anterior cingulate cortex dysfunction in attention deficit hyperactivity disorder revealed by fMRI and the Continuing Stroop.  Biol Psychiatry. 1999;  45 (12) 1542-1552
    CrossrefPubMedGoogle Scholar
  • 81 Rubia K, Overmeyer S, Taylor E, Brammer M, Williams S C, Simmons A, Bullmore E T. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI.  Am J Psychiatry. 1999;  156 (6) 891-896
    PubMedGoogle Scholar
  • 82 Vaidya C J, Austin G, Kirkorian G, Ridlehuber H W, Desmond J E, Glover G H, Gabrieli J D. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study.  Proc Natl Acad Sci USA. 1998;  95 (24) 14 494-14 499
    PubMedGoogle Scholar
  • 83 Teicher M H, Anderson C M, Polcari A, Glod C A, Mass L C, Renshaw P F. Functional deficits in basal ganglia of children with attention deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry.  Nat Med. 2000;  6 (4) 470-473
    PubMedGoogle Scholar
  • 84 Durston S, Tottenham N T, Thomas K M, Davidson M C, Egisti I M, Yang Y, Ulug A M, Casey B J. Differential pattern of striatal activation in young children with and without ADHD.  Biol Psychiatry. 2003;  53 (10) 871-878
    CrossrefPubMedGoogle Scholar
  • 85 Zang Y F, Jin Z, Weng X C, Zhang Y W, Yang L, Wang Y F, Seidman L J, Faraone S V. Functional MRI in attention-deficit hyperactivity disorder: Evidence for hypofrontality.  Brain Dev. 2005;  27 (8) 544-550
    PubMedGoogle Scholar
  • 86 Rubia K, Smith A B, Brammer M J, Toone B, Taylor E. Abnormal brain activation during inhibition and error detection in medication-naïve adolescents with ADHD.  Am J Psychiatry. 2005;  162 (6) 1067-1075
    CrossrefPubMedGoogle Scholar
  • 87 Zametkin A J, Nordahl T E, Gross M, King A C, Semple W E, Rumsey J, Hamburger S, Cohen R M. Cerebral glucose metabolism in adults with hyperactivity of childhood onset.  N Eng J Med. 1990;  323 (20) 1361-1366
    PubMedGoogle Scholar
  • 88 Zametkin A J, Liebenauer L L, Fitzgerald G A, King A C, Minkunas D V, Herscovitch P, Yamada E M, Cohen R M. Brain metabolism in teenagers with attention deficit hyperactivity disorder.  Arch Gen Psychiatry. 1993;  50 (5) 333-340
    PubMedGoogle Scholar
  • 89 Ernst M, Zametkin A J, Matochik J A, Jons P H, Cohen R M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A (fluorine-18) Fluorodopa positron emission tomographic study.  J Neurosci. 1998;  18 (15) 5901-5907
    PubMedGoogle Scholar
  • 90 Schweitzer J B, Faber T, Kilts C D, Votaw J, Hoffmann J M, Tune L. Regional cerebral blood flow during repeated exposure to vigilance task in adults with attention deficit hyperactivity disorder (Abstract).  Soc Neurosci. 1995;  21 1926
    PubMedGoogle Scholar
  • 91 Mattay V S, Bermann K F, Ostrem J L, Esposito G, Horn J D van, Bigelow L B, Weinberger D R. Dextroamphetamine enhances “neural network-specific” physiological signals: A positron-emission tomography rCBF study.  J Neurosci. 1996;  16 (15) 4816-4822
    PubMedGoogle Scholar
  • 92 Schweitzer J B, Lee D O, Hanford R B, Tagamets M A, Hoffman J M, Grafton S T, Kilts C D. A positron emission tomography study of methylphenidate with ADHD. Alterations in resting blood flow and predicting treatment response.  Neuropsychopharmacology. 2003;  28 (5) 967-973
    PubMedGoogle Scholar
  • 93 Lou H C, Rosa P, Pryds O, Karrebaek H, Lunding J, Cumming P, Gjedde A. ADHD: increased dopamine receptor availability linked to attention deficit and low neonatal cerebral blood flow.  Dev Med Child Neurol. 2004;  46 (3) 179-183
    CrossrefPubMedGoogle Scholar
  • 94 Schweitzer J B, Lee D O, Hanford R B, Zink C F, Ely T D, Tagamets M A, Hoffman J M, Grafton S T, Kilts C D. Effect of methylphenidate on executive functioning in adults with attention deficit/hyperactivity disorder: normalization of behavior but not related brain activity.  Biol Psychiatry. 2004;  56 (8) 597-606
    CrossrefPubMedGoogle Scholar
  • 95 Lou H C, Henriksen L, Bruhn P. Focal cerebral hypoperfusion in children with dysphoria and/or attention deficit disorder.  Arch Neurol. 1984;  41 (8) 825-829
    PubMedGoogle Scholar
  • 96 Lou H C, Henriksen L, Bruhn P. Focal cerebral dysfunction in developmental learning disabilities.  Lancet. 1990;  335 (8680) 8-11
    CrossrefPubMedGoogle Scholar
  • 97 Lou H C, Henriksen L, Bruhn P, Borner H, Nielsen J B. Striatal dysfunction in attention deficit and hyperkinetic disorder.  Arch Neurol. 1989;  46 (1) 48-52
    PubMedGoogle Scholar
  • 98 Sieg K G, Gaffney G R, Preston D F, Hellings J A. SPECT brain imaging abnormalities in attention deficit hyperactivity disorder.  Clin Nucl Med. 1995;  20 (1) 55-60
    PubMedGoogle Scholar
  • 99 Langleben D D, Austin G, Krikorian G, Ridlehuber H W, Goris M L, Strauss H W. Interhemispheric asymmetry of regional blood flow in prepubescent boys with attention deficit hyperactivity disorder.  Nucl Med Commun. 2001;  22 (12) 1333-1340
    CrossrefPubMedGoogle Scholar
  • 100 Kim B N, Lee J S, Cho S C, Lee D S. Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder.  Yonsei Med J. 2001;  42 (1) 19-29
    PubMedGoogle Scholar
  • 101 Langleben D D, Acton P D, Austin G, Elman I, Krikorian G, Monterosso J R, Portnoy O, Ridlehuber H W, Strauss H W. Effects of Methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit/hyperactivity disorder.  J Nucl Med. 2002;  43 (12) 1624-1629
    PubMedGoogle Scholar
  • 102 Kim B N, Lee J S, Shin M S, Cho S C, Lee D S. Regional cerebral perfusion abnormalities in attention deficit/hyperactivity disorder. Statistical mapping analysis.  Eur Arch Psychiatry Clin Neurosci. 2002;  252 (5) 219-225
    CrossrefPubMedGoogle Scholar
  • 103 Kaya G C, Pekcanlar A, Bekis R, Ada E, Miral S, Emiroglu N, Durak H. Technetium-99mHMPAO brain SPECT in children with attention deficit/hyperactivity disorder.  Ann Nucl Med. 2002;  16 (8) 527-531
    PubMedGoogle Scholar
  • 104 Rohde L A, Roman T, Szobot C, Cunha R D, Hutz M H, Biederman J. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention deficit/hyperactivity disorder.  Synapse. 2003;  48 (2) 87-89
    CrossrefPubMedGoogle Scholar
  • 105 Lorberboym M, Watemberg N, Nissenkorn A, Nir B, Lerman-Sagie T. Technetium 99 m ethylcysteinate dimer single-photon emission computed tomography (SPECT) during intellectual stress to children and adolescents with pure versus comorbid attention deficit/hyperactivity disorder (ADHD).  J Child Neurol. 2004;  19 (2) 91-96
    PubMedGoogle Scholar
  • 106 Oner O, Oner P, Aysev A, Kucuk O, Ibis E. Regional cerebral blood flow in children with ADHD: changes with age.  Brain Dev. 2005;  27 (4) 279-285
    CrossrefPubMedGoogle Scholar
  • 107 Dougherty D D, Bonab A A, Spencer T J, Rauch S L, Madras B K, Fischman A J. Dopamine transporter density in patients with attention deficit hyperactivity disorder.  Lancet. 1999;  354 (9196) 2132-2133
    CrossrefPubMedGoogle Scholar
  • 108 Krause K H, Dresel S H, Krause J, Kung H F, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography.  Neurosci Lett. 2000;  285 (2) 107-110
    CrossrefPubMedGoogle Scholar
  • 109 Dresel S, Krause J, Krause K H, la Fougere C, Brinkbaumer K, Kung H F, Hahn K, Tatsch K. Attention deficit hyperactivity disorder: binding of 99mTC-Trodat-1 to the dopamine transporter before and after methylphenidate treatment.  Eur J Nucl Med. 2000;  27 (10) 1518-1524
    PubMedGoogle Scholar
  • 110 Dyck C H van, Quinlan D M, Cretella L M, Staley J K, Malison R T, Baldwin R M, Seibl J P, Innis R B. Unaltered Dopamine Transporter Availability in Adult Attention Deficit Hyperactivity Disorder.  Am J Psychiatry. 2002;  159 (2) 309-312
    CrossrefPubMedGoogle Scholar
  • 111 Cheon K A, Ryu Y H, Kim Y K, Namkoong K, Kim C H, Lee J D. Dopamine transporter density in the basal ganglia assessed with (123I) IPT SPET in children with attention-deficit/hyperactivity disorder.  Eur J Nucl Med Mol Imaging. 2003;  30 (2) 306-311
    PubMedGoogle Scholar
  • 112 la Fougere C. (99mTC)Trodat-1: Szintigraphische Darstellung des Dopamintransporters im Gehirn bei gesunden Kontrollen, Patienten mit schizophrenen Störungen und Patienten mit Aufmerksamkeitsdefizit/Hyperaktivitätsstörungen. München: Dissertation an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München-Klinik und Polyklinik für Nuklearmedizin/Ludwig-Maximilians-Universität 2003: 1-76
    Google Scholar
  • 113 la Fougere C. US-Society of Nuclear Medicine Pressemitteilung der Jahrestagung Philadelphia, Pennsylvania: Controlling ADHD: German Scientists Use SPECT Imaging to Predict Patient Response to Drug Therapy. 2004: Posted June 22
    Google Scholar
  • 114 Rosa Neto P, Lou H, Cumming P, Pryds O, Gjedde A. Methyhlphenidate-evoced potentiation of extracellular dopamine in the brain of adolescents with premature birth: correlation with attentional deficit.  Ann NY Acad Sci. 2002;  965 434-439
    PubMedGoogle Scholar
  • 115 Vles J S, Feron F J, Hendriksen J G, Jolles J, Kroonenburgh M J van, Weber W E. Methylphenidate Down-Regulates the Dopamine Receptor and Transporter System in Children with Attention Deficit Hyperkinetic Disorder (ADHD).  Neuropediatrics. 2003;  34 (2) 77-80
    Article in Thieme ConnectPubMedGoogle Scholar
  • 116 Krause J, la Fougere C, Krause K H, Ackenheil M, Dresel S H. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD.  Eur Arch Psychiatry Clin Neurosci. 2005 Aug 17;  255 (6) 428-431
    CrossrefPubMedGoogle Scholar
  • 117 Rosa-Neto P, Lou H C, Cumming P, Pryds O, Karrebek H, Lunding J, Gjedde A. Methylphenidate-evoked changes in striatale dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder.  Neuroimage. 2005;  25 (3) 868-876
    CrossrefPubMedGoogle Scholar
  • 118 Feron F J, Hendriksen J G, Kroonenburg M J van, Blom-Coenjaerts C, Kessels A G, Jolles J, Weber W E, Vles J S. Dopamine Transporter in Attention-Deficit Hyperactivity Disorder Normalizes After Cessation of Methylphenidate.  Pediatr Neurol. 2005;  33 (3) 179-183
    CrossrefPubMedGoogle Scholar
  • 119 Patrick K S, Caldwell R W, Ferris R M, Breese G R. Pharmacology of the enantiomers of threo-methylphenidate.  J Pharmacol Exp Ther. 1987;  241 (1) 152-158
    PubMedGoogle Scholar
  • 120 Ding Y S, Fowler J S, Volkow N D, Dewey S L, Wang G J, Logan J, Gatley S J, Pappas N. Chiral drugs: comparison of the pharmacokinetics of [11C] d-threo and L-threo-methylphenidate in the human and baboon brain.  Psychopharmacology. 1997;  131 (1) 71-78
    CrossrefPubMedGoogle Scholar
  • 121 Volkow N D, Fowler J S, Wang G, Ding Y, Gatley S J. Mechanism of action of methylphenidate: insights from PET imaging studies.  J Atten Disord. 2002;  6 Suppl. 1 31-43
    PubMedGoogle Scholar
  • 122 Capp P K, Pearl P L, Conlon C. Methylphenidate HCL: therapy for attention-deficit hyperactivity disorder.  Expert Rev Neurother. 2005;  5 (3) 325-331
    CrossrefPubMedGoogle Scholar
  • 123 Nielsen J A, Chapin D S, Moore K E. Differential effects of d-amphetamine, beta-phenylethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and the efflux of dopamine metabolites into cerebroventricular perfusates of rats.  Life Sci. 1983;  33 (19) 1889-1907
    CrossrefPubMedGoogle Scholar
  • 124 Schweri M M, Skolnick P, Rafferty M F, Rice K C, Janowsky A J, Paul S M. (3H)Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenyl ethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters.  J Neurochem. 1985;  45 (2) 1062-1070
    CrossrefPubMedGoogle Scholar
  • 125 Gatley S J, Pan D, Chen R, Chaturvedi G, Ding Y X. Affinities of methylphenidate derivates for dopamine, norepinephrine and serotonin transporters.  Life Sci. 1996;  58 (12) 231-239
    PubMedGoogle Scholar
  • 126 Kuczenski R, Segal D S. Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine: comparison with amphetamine.  J Neurochem. 1997;  68 (5) 2032-2037
    PubMedGoogle Scholar
  • 127 Volkow N D, Wang G J, Fowler J S, Gatley S J, Logan J, Ding Y S, Hitzemann R, Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.  Am J Psychiatry. 1998;  155 (10) 1325-1331
    PubMedGoogle Scholar
  • 128 Volkow N D, Wang G, Fowler J S, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley S J, Gifford A, Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.  J Neurosci. 2001;  21 (2): RC121 1-5
    Google Scholar
  • 129 Volkow N D, Wang G J, Fowler J S, Logan J, Franceschi D, Maynard L, Ding Y S, Gatley S J, Gifford A, Zhu W, Swanson J M. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.  Synapse. 2002;  43 (3) 181-187
    CrossrefPubMedGoogle Scholar
  • 130 Iversen L L. Role of transmitter uptake mechanism in synaptic neurotransmission.  Br J Pharmacol. 1971;  41 (4) 571-591
    PubMedGoogle Scholar
  • 131 Shimada S, Kitayama S, Lin C L, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA.  Science. 1991;  254 (5031) 576-578
    PubMedGoogle Scholar
  • 132 Kuhar M J. Recent biochemical studies of dopamine transporter - a CNS drug target.  Life Sci. 1998;  62 (17 - 18) 1573-1575
    CrossrefPubMedGoogle Scholar
  • 133 Schenk J O. The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate.  Prog Drug Res. 2002;  59 111-131
    PubMedGoogle Scholar
  • 134 Bannon M J. The dopamine transporter: role in neurotoxiticity and human disease.  Toxicol Appl Pharmacol. 2005;  204 (3) 355-360
    CrossrefPubMedGoogle Scholar
  • 135 Spencer T J, Biederman J, Madras B K, Faraone S V, Dougerty D D, Bonab A A, Fischman A J. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter.  Biol Psychiatry. 2005;  57 (11) 1293-1300
    CrossrefPubMedGoogle Scholar
  • 136 Amara S G, Kuhar M J. Neurotransmitter transporters: recent progress.  Annu Rev Neurosci. 1993;  16 73-93
    PubMedGoogle Scholar
  • 137 Kung H F, Kim H J, Kung M P, Meegalla S K, Plossl K, Lee H K. Imaging of dopamine transporters in human brain with technetium-99 m TRODAT-1.  Eur J Nucl Med. 1996;  23 (11) 1527-1530
    PubMedGoogle Scholar
  • 138 Dresel S, Kung M P, Plossl K, Meegalla S K, Kung H F. Pharmacological effects of dopaminergic drugs on in vivo binding of (99 m Tc) Trodat-1 to the central dopamine transporters in rats.  Eur J Nucl Med. 1998;  25 (1) 31-39
    PubMedGoogle Scholar
  • 139 Mozley P D, Stubbs J B, Plossl K, Dresel S H, Barraclough E D, Alavi A, Araujo L I, Kung H F. Biodistribution and dosymetry of Trodat-1: a technetium-99 m tropane for imaging dopamine transporters.  J Nucl Med. 1998;  39 (12) 2069-2076
    PubMedGoogle Scholar
  • 140 Kugaya A, Fujita M, Innis R B. Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders.  Ann Nucl Med. 2000;  14 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 141 Piccini P P. Dopamine transporter: basic aspects and neuroimaging.  Mov Disord. 2003;  18 Suppl. 7 3-8
    CrossrefPubMedGoogle Scholar
  • 142 Solanto M V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.  Behav Brain Res. 1998;  94 (1) 127-152
    CrossrefPubMedGoogle Scholar
  • 143 Solanto M V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research.  Behav Brain Res. 2002;  130 (1 - 2) 65-71
    CrossrefPubMedGoogle Scholar
  • 144 Krause K H, Dresel S H, Krause J, la Fougere C, Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder.  Neurosci Biobehav Rev. 2003;  27 (7) 605-613
    Google Scholar
  • 145 Cook Jr E H, Stein M A, Krasowsky M D, Cox N J, Olkon D M, Kieffer J E, Leventhal B L. Association of attention deficit disorder and the dopamine transporter gene.  Am J Hum Genet. 1995;  56 (4) 993-998
    PubMedGoogle Scholar
  • 146 Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of association between attention deficit/hyperactivity disorder and a dopamine transporter polymorphism.  Mol Psychiatry. 1997;  2 (4) 311-313
    CrossrefPubMedGoogle Scholar
  • 147 Waldman I D, Rowe D C, Abramowitz A, Kozel S T, Mohr J H, Sherman S L, Cleveland H H, Sanders M L, Gard J M, Stever C. Association and linkage of the dopamine transporter gene and attention deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity.  Am J Hum Genet. 1998;  63 (6) 1767-1776
    CrossrefPubMedGoogle Scholar
  • 148 Daly G, Hawi Z, Fitzgerald M, Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children.  Mol Psychiatry. 1999;  4 (2) 192-196
    CrossrefPubMedGoogle Scholar
  • 149 Roman T, Rohde L A, Hutz M H. Polymorphism of the dopamine gene: influence response to methylphenidate in attention deficit-hyperactivity disorder.  Am J Pharmacogenomics. 2004;  4 (2) 83-92
    CrossrefPubMedGoogle Scholar
  • 150 Kent L. Recent advances in the genetics of attention deficit hyperactivity disorder.  Curr Psychiatr Rep. 2004;  6 (2) 143-148
    PubMedGoogle Scholar
  • 151 Bobb A J, Castellanos F X, Addington A M, Rapoport J L. Molecular genetic studies of ADHD: 1991 to 2004.  Am J Med Genet B Neuropsychiatr Genet. 2005;  132 (1) 109-125
    PubMedGoogle Scholar
  • 152 Cheon K A, Ryu Y H, Kim J W, Cho D Y. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention-deficit hyperactivity disorder: relating to treatment response to methylphenidate.  Eur Neuropsychopharmacol. 2005;  15 (1) 95-101
    CrossrefPubMedGoogle Scholar
  • 153 Mill J, XU X, Ronald A, Curran S, Price T, Knight J, Craig I, Sham P, Plomin R, Aherson P. Quantitative trait locus analysis of candidate gene alleles associated with attention-deficit hyperactivity disorder (ADHD) in five genes: DRD4, DAT1, DRD5, SNAP-25 and 5HT1B.  Am J Med Genet B Neuropsychiatr Genet. 2005;  133 (1) 68-73
    PubMedGoogle Scholar
  • 154 Feng Y, Wigg K G, Makkar R, Ickowicz A, Pathare T, Tannock R, Roberts W, Malone M, Kennedy J L, Schachar R, Barr C L. Sequence variation in the 3'-untranslateted region of the dopamine transporter gene and attention-deficit hyperactivity disorder (ADHD).  Am J Med Genet B Neuropsychiatr Genet. 2005;  139 (1) 1-6
    PubMedGoogle Scholar
  • 155 McGough J J. Attention-deficit/hyperactivity disorder pharmacogenomics.  Biol Psychiatry. 2005;  57 (11) 1367-1373
    CrossrefPubMedGoogle Scholar
  • 156 Swanson J M, Volkow N D. Serum and brain concentrations of methylphenidate: implications for use and abuse.  Neurosci Biobehav Rev. 2003;  27 (7) 615-621
    CrossrefPubMedGoogle Scholar
  • 157 Volkow N D, Wang G J, Fowler J S, Ding Y S. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder.  Biol Psychiatry. 2005;  57 (11) 1410-1415
    CrossrefPubMedGoogle Scholar
  • 158 O'Donell P. Dopamine gating of forebrain neural ensembles.  Eur J Neurosci. 2003;  17 (3) 429-435
    CrossrefPubMedGoogle Scholar
  • 159 Kiyatkin E A, Rebec G V. Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats.  J Neurophysiol. 1996;  75 (1) 142-153
    PubMedGoogle Scholar
  • 160 Koob G F. Hedonic valence, dopamine and motivation.  Mol Psychiatry. 1996;  1 (3) 186-189
    PubMedGoogle Scholar
  • 161 Jonkman L M, Kemmer C, Verbaten M N, Koelega H S, Camferman G, Gaag R J, Buitelaar J K, Engeland H van. Effects of methylphenidate on event related potentials and performance of attention-deficit hyperactivity disorder children in auditory and visual selective attention tasks.  Biol Psychiatry. 1997;  41 (6) 690-702
    CrossrefPubMedGoogle Scholar
  • 162 Moll G H, Heinrich H, Trott G E, Wirth S, Rothenberger A. Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate.  Neurosci Lett. 2000;  284: (1 - 2) 121-125
    CrossrefPubMedGoogle Scholar
  • 163 Moll G H, Heinrich H, Rothenberger A. Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention deficit hyperactivity disorder.  Acta Psych Scand. 2003;  107 (1) 69-72
    PubMedGoogle Scholar
  • 164 Hawk Jr L W, Yartz A R, Pelham Jr W E, Lock T M. The effects of methylphenidate on prepulse inhibition during attend and ignored prestimuli among boys with attention-deficit hyperactivity disorder.  Psychopharmacology (Berl). 2003;  165 (2) 118-127
    PubMedGoogle Scholar
  • 165 Shafritz K M, Marchione K E, Gore J C, Shaywitz S E, Shaywitz B A. The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder.  Am J Psychiatry. 2004;  161 (11) 1190-1197
    CrossrefPubMedGoogle Scholar
  • 166 Carey M B, Diewald L M, Esposito F J, Pellicano M P, Gironi Carnevale U A, Sergeant J A, Papa M, Sadile A G. Differential distribution, affinity and plasticity of dopamine D1 and D2 receptors in the target sites of the mesolimbic system in an animal model of ADHD.  Behav Brain Res. 1998;  94 (1) 173-185
    CrossrefPubMedGoogle Scholar
  • 167 Ilgin N, Senol S, Gucuyener K, Gokcora N, Sener S. Is increased D2 receptor availability associated with response to stimulant medication in ADHD.  Dev Med Child Neurol. 2001;  43 (11) 755-760
    CrossrefPubMedGoogle Scholar
  • 168 Seeman P, Madras B. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis.  Behav Brain Res. 2002;  130 (1 - 2) 79-83
    CrossrefPubMedGoogle Scholar
  • 169 Volkow N D, Fowler J S, Wang G J. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans.  J Psychopharmacol. 1999;  13 (4) 337-345
    PubMedGoogle Scholar
  • 170 Arnsten A F, Dudley A G. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoreceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder.  Behav Brain Funct. 2005;  1 (1) 2
    CrossrefPubMedGoogle Scholar
  • 171 Volkow N D, Swanson J M. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.  Am J Psychiatry. 2003;  160 (11) 1909-1918
    CrossrefPubMedGoogle Scholar
  • 172 Federici M, Geracitano R, Bernardi G, Mercuri N B. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain.  Biol Psychiatry. 2005;  57 (4) 361-365
    CrossrefPubMedGoogle Scholar
  • 173 Elliott J M, Beveridge T J. Psychostimulants and monoamine transporters: upsetting the balance.  Curr Opin Pharmacol. 2005;  5 (1) 94-100
    PubMedGoogle Scholar
  • 174 Viggiano D, Vallone D, Sadile A. Dysfunctions in dopamine and ADHD: evidence from animals and modelling.  Neural Plast. 2004;  11 (1 - 2) 97-114
    PubMedGoogle Scholar
  • 175 Shi W X, Pun C L, Zhou Y. Psychostimulants induce low-frequency oscillations in the firing activity of dopamine neurons.  Neuropsychopharmacology. 2004;  29 (12) 2160-2167
    CrossrefPubMedGoogle Scholar
  • 176 Madras B K, Miller G M, Fischman A J. The dopamine transporter and attention-deficit/hyperactivity disorder.  Biol Psychiatry. 2005;  57 (11) 1397-1409
    CrossrefPubMedGoogle Scholar
  • 177 Dyck C H van, Saibyl J P, Malison R T, Laruelle M, Wallace E, Zoghbi S S, Zea-Ponce Y, Baldwin R M, Charney D S, Hoffer P B. Age related decline in striatal dopamine transporter binding with iodine-beta-CIT SPECT.  J Nucl Med. 1995;  36 (7) 1175-1181
    PubMedGoogle Scholar
  • 178 Mozley P D, Kim H J, Gur R C, Tatsch K, Muenz L R, McElgin W T, Kung M P, Mu M, Myers A M, Kung H F. Iodine-(123i)IPT SPECT imaging of CNS dopamine transporters: non linear effect of normal aging on striatal uptake values.  J Nucl Med. (1996)-37;  (12) 1965-1970
    PubMedGoogle Scholar
  • 179 Meng S Z, Ozawa Y, Itoh M, Takashima S. Developmental and age related changes of dopamine transporters, and dopamine D1 and D2 receptors in human basal ganglia.  Brain Res. 1999;  843 (1 - 2) 136-144
    CrossrefPubMedGoogle Scholar
  • 180 Volkow N D, Ding Y S, Fowler J S, Wang G J, Logan J, Gatley S J, Hitzemann R, Smith G, Fields S D, Gur R. Dopamine transporter decrease with age.  J Nucl Med. 1996;  37 (4) 554-559
    PubMedGoogle Scholar
  • 181 Dyck C H van, Seibl J P, Malison R T, Laruelle M, Zoghbi S S, Baldwin R M, Innis R B. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries.  Am J Geriatr Psychiatry. 2002;  10 (1) 36-46
    PubMedGoogle Scholar
  • 182 Erixon-Lindroth N, Farde L, Wahlin T B, Sovago J, Halldin C, Backman L. The role of the striatal dopamine transporter in cognitive aging.  Psychiatry Res. 2005;  138 (1) 1-12
    PubMedGoogle Scholar
  • 183 Polanczyk G, Zeni C, Genro J P, Roman T, Hutz M H, Rohde L A. Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics.  Pharmacogenomics. 2005;  6 (3) 225-234
    CrossrefPubMedGoogle Scholar
  • 184 Purper-Quakil D, Wohl M, Mouren M C, Verpillat P, Ades J, Gorwood P. Meta-analysis of family-based association between the dopamine transporter gene and attention deficit hyperactivity disorder.  Psychiatr Genet. 2005;  15 (1) 53-59
    CrossrefPubMedGoogle Scholar
  • 185 Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.  Biol Psychiatry. 2005;  57 (3) 229-238
    CrossrefPubMedGoogle Scholar
  • 186 Janowsky A, Mah C, Johnson R A, Cunningham C L, Philipps T J, Crabbe J C, Eshleman A J, Belknap J K. Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice.  J Pharmacol EXP Ther. 2001;  298 (2) 634-643
    PubMedGoogle Scholar
  • 187 Buck K, Lischka T, Dorow J, Crabbe J. Mapping quantitative trait loci that regulate sensitivity and tolerance to quinpirole, a dopamine mimetic selective for D(2)/D(3) receptors.  Am J Med Genet. 2000;  96 (5) 696-705
    CrossrefPubMedGoogle Scholar
  • 188 Greenwood T A, Kelose J R. Promotor and intronic variants affect the transcriptional regulation of the human dopamine transporter gene.  Genomics. 2003;  82 (5) 511-520
    CrossrefPubMedGoogle Scholar
  • 189 Biederman J. Attention-deficit/hyperactivity disorder: a selective overview.  Biol Psychiatry. 2005;  57 (11) 1215-1220
    CrossrefPubMedGoogle Scholar
  • 190 Birnbaum H G, Kessler R C, Lowe S W, Secnik K, Greenberg P E, Leong S A, Swensen A R. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.  Curr Med Res Opin. 2005;  21 (2) 195-206
    CrossrefPubMedGoogle Scholar
  • 191 Nigg J T, Willcutt E G, Doyle A E, Sonuga-Barke E J. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes?.  Biol Psychiatry. 2005;  57 (11) 1224-1230
    CrossrefPubMedGoogle Scholar

Dr. Markus Huber

Zentrum für psychische Gesundheit · Psychiatrie-Sanitätsbetrieb Bruneck

Spitalgasse 11

39031 Bruneck/Südtirol

Italien

Email: markus.huber@sb-bruneck.it

      >